Holen Sie sich die Stockscreener-App
13.12
4.02%
-0.55
Handel nachbörslich:
12.91
-0.21
-1.60%
Schlusskurs vom Vortag:
$13.67
Offen:
$13.68
24-Stunden-Volumen:
76,984
Relative Volume:
0.61
Marktkapitalisierung:
$348.74M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+1.16%
1M Leistung:
-3.53%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$12.95
$13.68
1-Wochen-Bereich:
$12.94
$14.78
52-Wochen-Spanne:
$11.81
$16.20
Carlsmed Inc Stock (CARL) Company Profile
Firmenname
Carlsmed Inc
Sektor
Branche
Telefon
858-295-9290
Adresse
1800 ASTON AVENUE, CARLSBAD
Vergleichen Sie CARL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CARL
Carlsmed Inc
|
13.12 | 363.36M | 0 | 0 | 0 | 0.00 |
|
VEEV
Veeva Systems Inc
|
286.59 | 48.92B | 2.97B | 809.93M | 1.33B | 4.8743 |
|
TEM
Tempus Ai Inc
|
96.39 | 17.25B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
DOCS
Doximity Inc
|
65.61 | 13.59B | 550.17M | 201.35M | 232.07M | 1.00 |
|
HQY
Healthequity Inc
|
90.52 | 7.99B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
35.70 | 7.14B | 906.14M | -52.62M | 89.62M | -0.3621 |
Carlsmed Inc Stock (CARL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-18 | Eingeleitet | BTIG Research | Buy |
| 2025-08-18 | Eingeleitet | BofA Securities | Buy |
| 2025-08-18 | Eingeleitet | Goldman | Buy |
| 2025-08-18 | Eingeleitet | Piper Sandler | Overweight |
| 2025-08-18 | Eingeleitet | Truist | Buy |
Carlsmed Inc Aktie (CARL) Neueste Nachrichten
Earnings Preview: Carlsmed to Report Financial Results Post-market on August 28 - 富途牛牛
People moves: Michael Kaplan rejoins StandardAero as legal chief as Jenifer Kamocsay moves over to Carlsmed - | Governance Intelligence
Carlsmed names Jennifer Kamocsay as CLO and secretary - Medical Buyer
Carlsmed, Inc. Appoints Jennifer Kamocsay as Chief Legal Officer and Secretary - Orthopedics This Week
Carlsmed appoints Jenifer Kamocsay as chief legal officer By Investing.com - Investing.com Nigeria
Carlsmed appoints Jennifer Kamocsay as CLO, secretary - TipRanks
Carlsmed appoints Jenifer Kamocsay as chief legal officer - Investing.com India
Carlsmed, Inc. Appoints Jennifer Kamocsay as Chief Legal Officer and Secretary - GlobeNewswire Inc.
Carlsmed, Inc. Selected for Inclusion in Russell 2000 Index - 富途牛牛
Carlsmed joins Russell 2000 Index following Q3 IPO - MSN
Carlsmed announces inclusion in Russell 2000 Index - TipRanks
Carlsmed, Inc. Selected for Inclusion in Russell 2000® Index - MarketScreener
AI-Powered Spine Surgery Innovator Carlsmed Joins $9T Russell 2000 Index Following Successful IPO - Stock Titan
AI medtech firm Carlsmed prices $100.5M IPO - MSN
AI medtech firm Carlsmed to sell 6.7M shares in IPO - MSN
Goldman Sachs highlights two high-potential stocks: AI marketing platform Braze (BRZE.US) and medical technology company Carlsmed (CARL.US), assigning them a 'Buy' rating. - 富途牛牛
Carlsmed initiated with Buy at Truist on business potential - MSN
Carlsmed Q2 2025 revenue up 99% to USD 12.1M - Medical Buyer
Carlsmed stock rating reiterated at Buy by Goldman Sachs on growth outlook - Investing.com Australia
Carlsmed, Inc.: Strong Financial Performance and Growth Potential Justify Buy Rating - TipRanks
Carlsmed, Inc.: Strong Performance and Promising Growth Prospects with Upcoming Product Launch - TipRanks
UPDATECarlsmed® Reports Second Quarter 2025 Financial Results - The Manila Times
Carlsmed Reports Strong Growth in Q2 2025 Earnings - TipRanks
Carlsmed 2025 Q2 Earnings Strong Revenue Growth Despite Widening Net Loss - AInvest
Carlsmed: A High-Growth AI-Driven MedTech Play in Spine Surgery - AInvest
Earnings call transcript: Carlsmed’s Q2 2025 revenue surges, stock rises - Investing.com
Carlsmed Q2 Loss Narrows, Revenue Rises - MarketScreener
Carlsmed reports second quarter 2025 financial results - MarketScreener
Carlsmed® Q2 2025 Financial Performance: Assessing Long-Term Growth Potential in the AI-Driven Spine Surgery Revolution - AInvest
CARLSMED, INC. SEC 10-Q Report - TradingView
Carlsmed® Reports Second Quarter 2025 Financial Results - The Manila Times
Carlsmed, Inc.'s Q2 2025 Performance and Strategic Momentum: A Disruptive Force in AI-Driven Spine Surgery - AInvest
99% Growth: AI Spine Surgery Pioneer Carlsmed Hits $12.1M Revenue, Expands into Cervical Procedures - Stock Titan
Carlsmed CARL 2025Q2 Earnings Preview Upside Potential on AI-Driven Spine Solutions - AInvest
Two AI Small Caps Nobody Noticed - Nanalyze
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Truist Securities initiates coverage on Carlsmed stock with Buy rating By Investing.com - Investing.com Australia
Why Is Carlsmed Stock Gaining Monday?Carlsmed (NASDAQ:CARL) - Benzinga
Truist Initiates Buy on Carlsmed with Focus on Business Growth Potential - AInvest
Carlsmed initiated with Buy at Truist on business potential (CARL) - Seeking Alpha
BofA Securities Initiates Coverage on Carlsmed With Buy Rating, $16 Price Target - MarketScreener
This Synaptics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Goldman Sachs Initiates Coverage on Carlsmed With Buy Rating, $19 Price Target - MarketScreener
Carlsmed initiated with a Buy at BTIG - TipRanks
Truist Securities initiates coverage on Carlsmed stock with Buy rating - Investing.com
Truist Initiates Carlsmed at Buy With $18 Price Target - MarketScreener
Piper Sandler initiates coverage on Carlsmed with an Overweight rating, PT of $18. - AInvest
Buy Rating for Carlsmed: Innovative Aprevo Technology and Strong Growth Projections Justify Premium Valuation - TipRanks
Carlsmed stock initiated with Buy rating at BTIG on customized implant tech - Investing.com
Finanzdaten der Carlsmed Inc-Aktie (CARL)
Es liegen keine Finanzdaten für Carlsmed Inc (CARL) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
Carlsmed Inc-Aktie (CARL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Sidow Kevin | Director |
Jul 24 '25 |
Buy |
15.00 |
13,333 |
199,995 |
59,566 |
| Mittendorff Robert II | Director |
Jul 24 '25 |
Buy |
15.00 |
1,333,333 |
19,999,995 |
5,013,839 |
| ROOT JONATHAN D | Director |
Jul 24 '25 |
Buy |
15.00 |
466,666 |
6,999,990 |
483,999 |
| YOUNG PHILIP M | Director |
Jul 24 '25 |
Buy |
15.00 |
59,999 |
899,985 |
53,333 |
8.35%
1.76%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):